CME: Hypertonie und die COVID-19-Pandemie: Was in der medizinischen Praxis zu beachten ist [CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice]

Détails

ID Serval
serval:BIB_107E76CC8925
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
CME: Hypertonie und die COVID-19-Pandemie: Was in der medizinischen Praxis zu beachten ist [CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice]
Périodique
Praxis
Auteur(s)
Wuerzner G., Waeber B.
ISSN
1661-8157 (Print)
ISSN-L
1661-8157
Statut éditorial
Publié
Date de publication
02/2021
Peer-reviewed
Oui
Volume
110
Numéro
2
Pages
60-64
Langue
allemand
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
CME: Hypertension and the COVID-19 Pandemic: What to Consider in Medical Practice Abstract. The COVID-19 pandemic represents a major public health problem. A fraction of the population is at increased risk of developing complications of this disease, in particular older subjects as well as diabetic, obese and hypertensive patients. With regard to patients with high blood pressure, the existence of an increased risk remains to be confirmed in large controlled trials. So far the findings regarding this question are reassuring, whether these patients are treated or not. There seems to be no reason to worry when using blockers of the renin-angiotensin system. The observations available to date suggest that COVID-19 vaccine can be administered safely to hypertensive patients. In conclusion, there is no reason to implement changes in the care of hypertensive patients due to the pandemic.
Mots-clé
Angiotensin-Converting Enzyme Inhibitors/pharmacology, Antihypertensive Agents/pharmacology, Antihypertensive Agents/therapeutic use, COVID-19, COVID-19 Vaccines, Humans, Hypertension/drug therapy, Hypertension/epidemiology, Pandemics, Renin-Angiotensin System, SARS-CoV-2, Blocker des Renin-Angiotensin-Systems, Bluthochdruck, COVID-19 vaccine, Hypertonie, Risikofaktoren, antihypertensive Therapie, antihypertensive therapy, blockers of the renin-angiotensin system, facteurs de risque, hypertension, hypertension artérielle, loqueurs du système rénine-angiotensine, risk factors, traitement antihypertenseur, vaccination Covid-19
Pubmed
Création de la notice
23/02/2021 8:46
Dernière modification de la notice
16/07/2021 5:37
Données d'usage